Jeil Pharma Holdings제일파마홀딩스
002620 · KOSPI · ₩002620 · 제일파마홀딩스
- Market cap
- ₩112B
- Enterprise value
- ₩51B
- P/E
- 13.3×
- P/B
- 0.4×
- Dividend yield
- 1.0%
- ROE
- 2.7%
- Net margin
- 1.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−28.5% from the high
₩6,050Today: ₩7,020 – ₩7,200₩9,850
Returns
- 1W−4.7%
- 1M−6.1%
- 3M−2.2%
- 6M−21.3%
- YTD−12.4%
- 1Y−15.8%
- Volume today
- 1,188
- 0.3× the 20-day average
- Traded today
- ₩8.4M
- Listed shares
- 15,973,355
- EPS (12 months)
- ₩528
- Earnings yield 7.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 30 of 100 (50 is a normal day for this stock).
- MomentumWeak-8% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Jeil Pharma Holdings stock overview
Jeil Pharma Holdings (제일파마홀딩스, KRX: 002620) is listed on KOSPI, in the Business services sector. Jeil Pharma Holdings is a Korean holding company that holds the shares of its subsidiaries and affiliates, including Jeil Pharmaceutical and Jeil Health Science, and earns income mainly from management consulting fees, rental of its head office building and other investment assets, and equity-method gains. Its shares closed at ₩7,040 on Oct 26, 2026, down 2.22% on the day, giving it a market value of ₩112B.
Key facts
- Market cap
- ₩112B
- Sector
- Business services
- Latest price change
- −2.22%
- As of
- Oct 26, 2026
- Main business
- Jeil Pharma Holdings is a Korean holding company that holds the shares of its subsidiaries and affiliates, including Jeil Pharmaceutical and Jeil Health Science, and earns income mainly from management consulting fees, rental of its head office building and other investment assets, and equity-method gains.
Quick answers about Jeil Pharma Holdings
- What does Jeil Pharma Holdings do?
- Jeil Pharma Holdings is a Korean holding company that holds the shares of its subsidiaries and affiliates, including Jeil Pharmaceutical and Jeil Health Science, and earns income mainly from management consulting fees, rental of its head office building and other investment assets, and equity-method gains. Its subsidiaries manufacture and sell prescription and over-the-counter pharmaceuticals, and Jeil & Partners acts as a sales agent for Jeil Pharmaceutical's finished drugs.
- What is the market cap of Jeil Pharma Holdings?
- The market capitalisation of Jeil Pharma Holdings was ₩112B at the close on Oct 26, 2026.
- Who are the largest shareholders of Jeil Pharma Holdings?
- According to the latest official filings, the largest reported holders are Han Seung-su (73.21%, as of Jul 15, 2026); Han Sang-cheol (10.64%, as of Jul 15, 2026); National Pension Service (0.44%, as of Dec 31, 2025).
- When is the next earnings report from Jeil Pharma Holdings?
- Korean companies rarely announce results dates in advance. Based on when Jeil Pharma Holdings filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Jeil Pharma Holdings?
- Yes. The National Pension Service held 0.44% of Jeil Pharma Holdings shares as of Dec 31, 2025.
Company profile
Jeil Pharma Holdings is a Korean holding company that holds the shares of its subsidiaries and affiliates, including Jeil Pharmaceutical and Jeil Health Science, and earns income mainly from management consulting fees, rental of its head office building and other investment assets, and equity-method gains. Its subsidiaries manufacture and sell prescription and over-the-counter pharmaceuticals, and Jeil & Partners acts as a sales agent for Jeil Pharmaceutical's finished drugs.
Written by AI from the company's latest annual report.
- Korean name
- 제일파마홀딩스
- Sector
- Business services
- Themes
- Pharmaceuticals
- CEO
- 한상철
- Founded
- Mar 1959
- Listed
- Jan 1988
- Listed shares
- 15,973,355
- Fiscal year ends
- Month 12
- Website
- www.jeilpharm.co.kr
Similar companies
- S-1012750 · ₩3.5T₩93,300−2.81%
- Cheil Worldwide030000 · ₩2.2T₩19,170−1.13%
- Doosan Tesna131970 · ₩1.8T₩95,400−5.92%
- Lotte Tour Development032350 · ₩805B₩10,100−5.96%
- Soulbrain Holdings036830 · ₩737B₩35,950−3.36%
- Innocean Worldwide214320 · ₩691B₩17,270−1.99%
- Korea Ratings034950 · ₩458B₩100,800−0.20%
- GC005250 · ₩427B₩9,090−2.57%
Recent filings
See all- Corporate value-up planOct 22, 2026
- Amended: Half-year report (Jun 2026)Aug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 15, 2026
- Insider shareholding reportJul 15, 2026
Titles in Korean until English translations are added.
Also known as: Jeil Pharma Holdings / 제일파마홀딩스 / 002620 / KRX:002620
Source: KRX statistical information